Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells

Androgen receptor (AR) signaling is fundamental to prostate cancer (PC) progression, and hence, androgen deprivation therapy (ADT) remains a mainstay of treatment. However, augmented AR signaling via both full length AR (AR-FL) and constitutively active AR splice variants, especially AR-V7, is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurana, Namrata, Chandra, Partha K., Kim, Hogyoung, Abdel-Mageed, Asim B., Mondal, Debasis, Sikka, Suresh C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022272/
https://www.ncbi.nlm.nih.gov/pubmed/31940946
http://dx.doi.org/10.3390/antiox9010068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022272/
https://www.ncbi.nlm.nih.gov/pubmed/31940946
http://dx.doi.org/10.3390/antiox9010068

Ejemplares similares